Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.56 |
| ▸ | RXRB | P28702 | 5/20 | 0.56 |
| ▸ | RXRG | P48443 | 5/20 | 0.56 |
| ▸ | RARA | P10276 | 4/20 | 0.56 |
| ▸ | RARB | P10826 | 4/20 | 0.56 |
| ▸ | RARG | P13631 | 4/20 | 0.56 |
| ▸ | HNF4A | P41235 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140687 | 1.00 | RXRA (0.56) | RXRARXRBRXRGRARARARB | |
| Nitrous Acid SCHEMBL1140924 | 0.94 | RXRA (0.54) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6913861 | 0.93 | RXRA (0.49) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6913864 | 0.93 | RXRA (0.49) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6917516 | 0.91 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6917514 | 0.91 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6917805 | 0.91 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6917806 | 0.91 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6915730 | 0.90 | RXRA (0.55) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6915727 | 0.90 | RXRA (0.55) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | claimed |
| US-20050220774-A1 | Methods of inducing differentiation in ex vivo expanded stem cells | GAMIDA CELL LTD. (IL) | 2005-10-06 | — | — | US | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| EP-2206773-B1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD (IL) | 2012-07-11 | — | — | EP | disclosed |
| US-7955852-B2 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. (IL) | 2011-06-07 | — | — | US | disclosed |
| EP-2305794-A1 | Expansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2011-04-06 | — | — | EP | disclosed |
| US-20110033427-A1 | Expansion Of Renewable Stem Cell Populations | GAMIDA CELL LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | CANAN-KOCH STACIE (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | disclosed |
| EP-1336600-A2 | Dimer-selective RXR modulators and methods for their use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | disclosed |
| US-6545049-B1 | E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof | LIGAND PHARMACEUTICALS INCORPORATED | 2003-04-08 | — | — | US | disclosed |
| EP-0873295-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019072-A1 | Dimer-selective RXR modulators and methods for their use | RXRG, RXRB, RXRA | RXRA 3/4885RXRB 2/4885RXRG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.